| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Shan He, Karam Nader, Julen Segura Abarrategi, Harbil Bediaga, Deyani Nocedo-Mena, Estefania Ascencio, Gerardo M Casanola-Martin, Idoia Castellanos-Rubio, Maite Insausti, Bakhtiyor Rasulev, Sonia Arrasate, Humberto González-Día. NANO.PTML model for read-across prediction of nanosystems in neurosciences. computational model and experimental case of study. Journal of nanobiotechnology. vol 22. issue 1. 2024-07-24. PMID:39044265. |
nanoparticles (nps) in biomedical field are garnering growing attention as neurodegenerative disease drugs (ndds) carrier to the central nervous system. |
2024-07-24 |
2024-07-26 |
Not clear |
| Valeria De Matteis, Simona Martano, Paolo Pellegrino, Chiara Ingrosso, Daniele Costa, Stefano Mazzotta, Jose L Toca-Herrera, Rosaria Rinaldi, Mariafrancesca Cascion. Green silver nanoparticles: Prospective nanotools against neurodegenerative cell line model. Ibrain. vol 10. issue 2. 2024-06-25. PMID:38915951. |
in this study, the effects of green chemistry-derived silver nps (agnps) were assessed in neuroblastoma cells, shsy-5y, which are considered a pivotal model for investigating neurodegenerative diseases. |
2024-06-25 |
2024-06-27 |
Not clear |
| Chinenye Edith Muolokwu, Bivek Chaulagain, Avinash Gothwal, Arun Kumar Mahanta, Benjamin Tagoe, Babita Lamsal, Jagdish Sing. Functionalized nanoparticles to deliver nucleic acids to the brain for the treatment of Alzheimer's disease. Frontiers in pharmacology. vol 15. 2024-06-10. PMID:38855744. |
the utilization of functionalized nps extends beyond a singular system, serving as a versatile platform for customization in related neurodegenerative diseases. |
2024-06-10 |
2024-06-14 |
Not clear |
| Mitra Pirhaghi, Fatemeh Mamashli, Faezeh Moosavi-Movahedi, Payam Arghavani, Ahmad Amiri, Bagher Davaeil, Mahya Mohammad-Zaheri, Zahra Mousavi-Jarrahi, Deepak Sharma, Ülo Langel, Daniel Erik Otzen, Ali Akbar Sabour. Cell-Penetrating Peptides: Promising Therapeutics and Drug-Delivery Systems for Neurodegenerative Diseases. Molecular pharmaceutics. 2024-03-05. PMID:38440998. |
our review presents and discusses research that utilizes cpps, either alone or in conjugation with nps, to mitigate the pathogenic effects of neurodegenerative diseases with particular reference to ad and pd. |
2024-03-05 |
2024-03-07 |
Not clear |
| Jacob S Shaw, Jeannie M Leoutsakos, Paul B Rosenber. The Relationship Between First Presenting Neuropsychiatric Symptoms in Older Adults and Autopsy-Confirmed Memory Disorders. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry. 2024-01-31. PMID:38296755. |
few studies have assessed the timing of nps onset in relation to pathological diagnoses of neurodegenerative diseases. |
2024-01-31 |
2024-02-03 |
Not clear |
| Cristóbal Pereira-Abello, Marcelino Cuesta-Izquierdo, Laudino López-Álvarez, Alfonso García-Viej. Identification of Neuropsychiatric Symptoms in Preclinical and Prodromal Stages in Dementias: Development of a Screening Test for Mild Behavioral Impairment. Psicothema. vol 36. issue 1. 2024-01-16. PMID:38227304. |
neuropsychiatric symptoms (nps) are a psychopathological dimension of neurodegenerative diseases, consisting of personality changes, behavioral disorders, and alterations in basic functions such as appetite or sleep, among others. |
2024-01-16 |
2024-01-18 |
Not clear |
| Katarzyna Sikorska, Krzysztof Sawicki, Magdalena Czajka, Lucyna Kapka-Skrzypczak, Marcin Kruszewski, Kamil Brzósk. Adverse Effects of Non-Metallic Nanoparticles in the Central Nervous System. Materials (Basel, Switzerland). vol 16. issue 23. 2023-12-09. PMID:38068008. |
hence, a closer look at the impact of non-metallic nps on neural tissue is necessary, especially in the context of the increasing prevalence of neurodegenerative diseases. |
2023-12-09 |
2023-12-17 |
Not clear |
| Min Chen, Tianshu W. Nanoparticles and neurodegeneration: Insights on multiple pathways of programmed cell death regulated by nanoparticles. The Science of the total environment. 2023-11-26. PMID:38008311. |
currently, nanoparticles (nps) are extensively applied in the diagnosis and treatment of neurodegenerative diseases (nds). |
2023-11-26 |
2023-11-28 |
Not clear |
| Mohammad Azam Ansari, Takshashila Tripathi, Baskar Venkidasamy, Alan Monziani, Govindasamy Rajakumar, Mohammad N Alomary, Sami A Alyahya, Oriane Onimus, Naomi D'souza, Md Abul Barkat, Ebtesam A Al-Suhaimi, Ramkumar Samynathan, Muthu Thiruvengada. Multifunctional Nanocarriers for Alzheimer's Disease: Befriending the Barriers. Molecular neurobiology. 2023-11-15. PMID:37966683. |
in the present review, we discussed the role of metal-based nps, polymeric nanogels, nanocarrier systems such as liposomes, solid lipid nps, polymeric nps, exosomes, quantum dots, dendrimers, polymersomes, carbon nanotubes, and nanofibers and surfactant-based systems for the therapy of neurodegenerative diseases. |
2023-11-15 |
2023-11-20 |
Not clear |
| Susu Kong, Xi Wen, Yueju Wang, Rong Tan, Huiling Li, Yifeng T. Development of a P-tau217 Electrochemiluminescent Immunosensor Reinforced with Au-Cu Nanoparticles for Alzheimer's Disease Precaution. ACS chemical neuroscience. 2023-11-08. PMID:37939215. |
to simply and rapidly detect the highly phosphorylated tau protein at threonine 217 (p-tau217) as a precautionary measure against alzheimer's disease and distinguish it from other neurodegenerative diseases, a novel immunosensor was prepared using luminol as the electrochemiluminescent (ecl) sensing probe reinforced by au-cu nanoparticles (au-cu nps). |
2023-11-08 |
2023-11-20 |
human |
| Govinda R Navale, Rahul Chauhan, Saakshi Saini, Partha Roy, Kaushik Ghos. Effect of cycloastragenol and punicalagin on Prp(106-126) and Aβ(25-35) oligomerization and fibrillizaton. Biophysical chemistry. vol 302. 2023-09-21. PMID:37734278. |
recent years have seen a significant increase in the exploration and study of natural products (nps) from plant and microbial sources for their therapeutic potential against several diseases, including cancer, diabetes, cardiovascular disease, and neurodegenerative diseases. |
2023-09-21 |
2023-10-07 |
Not clear |
| Linyan Duan, Xingfan Li, Rong Ji, Zhizhong Hao, Mingyue Kong, Xuejun Wen, Fangxia Guan, Shanshan M. Nanoparticle-Based Drug Delivery Systems: An Inspiring Therapeutic Strategy for Neurodegenerative Diseases. Polymers. vol 15. issue 9. 2023-05-14. PMID:37177342. |
in this article, we provided an overview of the types and administration routes of nps, highlighted the preclinical and clinical studies of nddss in neurodegenerative diseases, and summarized the combined therapeutic strategies in the management of neurodegenerative diseases. |
2023-05-14 |
2023-08-14 |
Not clear |
| Rebecca Maher, Almudena Moreno-Borrallo, Dhruvi Jindal, Binh T Mai, Eduardo Ruiz-Hernandez, Andrew Harki. Intranasal Polymeric and Lipid-Based Nanocarriers for CNS Drug Delivery. Pharmaceutics. vol 15. issue 3. 2023-03-29. PMID:36986607. |
polymer and lipid-based nanoparticles (nps) are reported to penetrate the blood-brain barrier (bbb) and have been extensively assessed in in vitro and animal models of glioblastoma, epilepsy, and neurodegenerative disease. |
2023-03-29 |
2023-08-14 |
Not clear |
| Xuxu Xu, Chaowei Han, Pengcheng Wang, Feimeng Zho. Natural products targeting cellular processes common in Parkinson's disease and multiple sclerosis. Frontiers in neurology. vol 14. 2023-03-27. PMID:36970529. |
a review from this perspective can provide insights into the search for and utilization of nps in treating the similar cellular processes common in major neurodegenerative diseases. |
2023-03-27 |
2023-08-14 |
Not clear |
| Michael J C Bray, Barry R Bryant, Aaron I Esagoff, Lisa N Richey, Carla Rodriguez, Akshay Krieg, Gardner McCullough, Jerry Tsai, William Tobolowsky, Sahar Jahed, C Munro Cullum, Christian LoBue, Zahinoor Ismail, Haijuan Yan, Constantine G Lyketsos, Matthew E Peter. Effect of traumatic brain injury on mild behavioral impairment domains prior to all-cause dementia diagnosis and throughout disease progression. Alzheimer's & dementia (New York, N. Y.). vol 8. issue 1. 2022-12-14. PMID:36514440. |
originally designed to evaluate behavioral disruption prior to dementia diagnosis, the mild behavioral impairment (mbi) construct relates nps to underlying neural circuit disruptions, with probable relevance across the progression of neurodegenerative disease. |
2022-12-14 |
2023-08-14 |
human |
| Maryam Ghahremani, Meng Wang, Hung-Yu Chen, Henrik Zetterberg, Eric Smith, Zahinoor Ismai. Plasma P-Tau181 and Neuropsychiatric Symptoms in Preclinical and Prodromal Alzheimer Disease. Neurology. 2022-11-02. PMID:36323521. |
however, the few studies assessing ad biomarkers in association with nps have often suffered from imprecision in capturing behavioral symptoms that represent sequalae of neurodegenerative disease. |
2022-11-02 |
2023-08-14 |
Not clear |
| Nicolò Montegiove, Eleonora Calzoni, Carla Emiliani, Alessio Cesarett. Biopolymer Nanoparticles for Nose-to-Brain Drug Delivery: A New Promising Approach for the Treatment of Neurological Diseases. Journal of functional biomaterials. vol 13. issue 3. 2022-09-22. PMID:36135560. |
in this review, various types of biodegradable polymer nps for drug delivery to the brain through the ntb route are discussed and particular attention is devoted to the treatment of neurological diseases such as glioblastoma and neurodegenerative diseases. |
2022-09-22 |
2023-08-14 |
Not clear |
| Rachel M Keszycki, Guadalupe Rodriguez, Andrea Locci, Hector D Orellana, Isabel Haupfear, Sky Dominguez, Daniel W Fisher, Hongxin Don. Characterization of apathy-like behaviors and their relationship to Aβ pathology in 5xFAD mice. Alzheimer's & dementia : the journal of the Alzheimer's Association. vol 17 Suppl 3. 2022-02-03. PMID:35109153. |
alzheimer's disease (ad) is a neurodegenerative disease that causes progressive cognitive decline and neuropsychiatric symptoms (nps) with apathy being highly common. |
2022-02-03 |
2023-08-13 |
mouse |
| N S Cherkasov, I V Kolykhalo. [Non-cognitive psychopathological symptoms in mild cognitive impairment]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. vol 121. issue 10. Vyp. 2. 2021-12-07. PMID:34870913. |
noncognitive psychopathological symptoms (nps) in elderly patients are increasingly attracting the attention of researchers in the field of neurodegenerative diseases. |
2021-12-07 |
2023-08-13 |
Not clear |
| Weihong Ji, Yan Li, Ruiyuan Liu, Zhiguo Lu, Linying Liu, Zhuyan Shi, Jie Shen, Xin Zhan. Synaptic vesicle-inspired nanoparticles with spatiotemporally controlled release ability as a "nanoguard" for synergistic treatment of synucleinopathies. Materials horizons. vol 8. issue 4. 2021-11-26. PMID:34821912. |
this study indicates that the synaptic vesicle-inspired nps may have the potential to open up a new avenue for the treatment of synucleinopathies, as well as other neurodegenerative diseases. |
2021-11-26 |
2023-08-13 |
Not clear |